Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will participate in two upcoming investor conferences.

Piper Jaffray 20^th Annual Health Care Conference

Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present on Wednesday, December 3, 2008 at 10:30 a.m. Eastern Time. A webcast of the presentation will be available live and for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “news and investor information” section.

In addition, Dr. Siegall will participate in a panel entitled “Novel Antibody Technologies,” at 12:00 p.m. Eastern Time on December 3, 2008. The conference is being held at The New York Palace Hotel.

RBC Capital Markets 2008 Healthcare Conference

Eric L. Dobmeier, Chief Business Officer, will participate in a panel entitled “Building A Pipeline of Partnered and Proprietary Drugs,” on Thursday, December 11, 2008 at 10:00 a.m. Eastern Time. The presentation will be available live and for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “news and investor information” section. The conference is being held at The Westin Times Square Hotel in New York.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company has four product candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33), SGN-35 and SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo and MedImmune, a subsidiary of AstraZeneca, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at www.seattlegenetics.com.